For patients with recurrent/metastatic HNSCC, combined chemotherapy with platinum and paclitaxel or 5-fluorouracil plus the EGFR monoclonal antibody cetuximab is the standard first-line therapeutic regimen, but consequential drug resistance is common and finally leads to the limited efficacy of treatment [2]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.